Ascites control by TIPS is more successful in patients with a lower paracentesis frequency and is associated with improved survival.
MELD score
decompensation
hepatic venous pressure gradient
liver cirrhosis
portal hypertension
refractory ascites
stents
transplant
Journal
JHEP reports : innovation in hepatology
ISSN: 2589-5559
Titre abrégé: JHEP Rep
Pays: Netherlands
ID NLM: 101761237
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
21
12
2018
revised:
18
03
2019
accepted:
09
04
2019
entrez:
11
2
2020
pubmed:
11
2
2020
medline:
11
2
2020
Statut:
epublish
Résumé
Refractory ascites is the main reason for the implantation of a transjugular intrahepatic portosystemic shunt (TIPS) in liver cirrhosis, but ascites control by TIPS fails in a relevant proportion of cases. Here, we investigated whether routine parameters pre-TIPS can predict persistent ascites after TIPS implantation and whether persistent ascites predicts long-term clinical outcome. A detailed retrospective analysis of 128 patients receiving expanded polytetrafluoroethylene-covered stents for the treatment of refractory ascites was performed. Persistent ascites post-TIPS was defined as the prolonged need for paracentesis >3 months after TIPS. The influence of demographics, laboratory results, pre-TIPS heart and liver ultrasound results, and invasive hemodynamic parameters on persistent ascites was evaluated by univariable and multivariable logistic regression. Predictors of the composite endpoint liver transplantation/death were analyzed using a multivariable Cox regression. Ascites control post-TIPS was achieved in 95/128 patients (74%), whereas ascites remained persistent in 33/128 cases (26%). On multivariable analysis, a lower paracentesis frequency pre-TIPS (odds ratio 1.672; 95% CI 1.253-2.355) and lower baseline creatinine levels (odds ratio 2.640; CI 1.201-6.607) were associated with ascites control. Patients with persistent ascites post-TIPS had and impaired transplant-free survival (median 10.0 TIPS-placement in patients with lower paracentesis frequency and creatinine levels is associated with superior ascites control. Thus, TIPS implantation should be considered in moderate decompensation and not as a last resort. Persistent ascites post-TIPS seems to be the only predictor of liver transplantation and death. The insertion of a transjugular intrahepatic portosystemic shunt (TIPS) in patients with refractory ascites should be considered in patients with moderate decompensation and not as a last resort, as lower paracentesis frequency and creatinine levels pre-TIPS are associated with superior ascites control. In turn, failure to control ascites seems to be the only predictor of liver transplantation and death.
Sections du résumé
BACKGROUND & AIMS
OBJECTIVE
Refractory ascites is the main reason for the implantation of a transjugular intrahepatic portosystemic shunt (TIPS) in liver cirrhosis, but ascites control by TIPS fails in a relevant proportion of cases. Here, we investigated whether routine parameters pre-TIPS can predict persistent ascites after TIPS implantation and whether persistent ascites predicts long-term clinical outcome.
METHODS
METHODS
A detailed retrospective analysis of 128 patients receiving expanded polytetrafluoroethylene-covered stents for the treatment of refractory ascites was performed. Persistent ascites post-TIPS was defined as the prolonged need for paracentesis >3 months after TIPS. The influence of demographics, laboratory results, pre-TIPS heart and liver ultrasound results, and invasive hemodynamic parameters on persistent ascites was evaluated by univariable and multivariable logistic regression. Predictors of the composite endpoint liver transplantation/death were analyzed using a multivariable Cox regression.
RESULTS
RESULTS
Ascites control post-TIPS was achieved in 95/128 patients (74%), whereas ascites remained persistent in 33/128 cases (26%). On multivariable analysis, a lower paracentesis frequency pre-TIPS (odds ratio 1.672; 95% CI 1.253-2.355) and lower baseline creatinine levels (odds ratio 2.640; CI 1.201-6.607) were associated with ascites control. Patients with persistent ascites post-TIPS had and impaired transplant-free survival (median 10.0
CONCLUSION
CONCLUSIONS
TIPS-placement in patients with lower paracentesis frequency and creatinine levels is associated with superior ascites control. Thus, TIPS implantation should be considered in moderate decompensation and not as a last resort. Persistent ascites post-TIPS seems to be the only predictor of liver transplantation and death.
LAY SUMMARY
BACKGROUND
The insertion of a transjugular intrahepatic portosystemic shunt (TIPS) in patients with refractory ascites should be considered in patients with moderate decompensation and not as a last resort, as lower paracentesis frequency and creatinine levels pre-TIPS are associated with superior ascites control. In turn, failure to control ascites seems to be the only predictor of liver transplantation and death.
Identifiants
pubmed: 32039356
doi: 10.1016/j.jhepr.2019.04.001
pii: S2589-5559(19)30031-X
pmc: PMC7001550
doi:
Types de publication
Journal Article
Langues
eng
Pagination
90-98Informations de copyright
© 2019 The Authors.
Références
Gut. 2000 Aug;47(2):288-95
pubmed: 10896924
J Hepatol. 2011 May;54(5):901-7
pubmed: 21145798
J Gastroenterol. 2011 Jan;46(1):78-85
pubmed: 20632194
J Hepatol. 2013 Nov;59(5):1081-93
pubmed: 23811307
Hepatology. 2018 Apr;67(4):1472-1484
pubmed: 29059466
Dig Liver Dis. 2018 Apr;50(4):323-330
pubmed: 29422242
AJR Am J Roentgenol. 1995 Jul;165(1):1-7
pubmed: 7785564
Dig Liver Dis. 2018 Jan;50(1):54-60
pubmed: 29102174
Gastroenterology. 2017 Jan;152(1):157-163
pubmed: 27663604
Liver Int. 2018 May;38(5):875-884
pubmed: 29105936
N Engl J Med. 2000 Jun 8;342(23):1701-7
pubmed: 10841872
Gastroenterology. 2017 May;152(6):1358-1365
pubmed: 28130066
Am J Physiol Gastrointest Liver Physiol. 2018 Oct 1;315(4):G484-G494
pubmed: 29746172
J Hepatol. 2016 Oct;65(4):692-699
pubmed: 27242316
Am J Physiol Gastrointest Liver Physiol. 2018 Feb 1;314(2):G179-G187
pubmed: 29051188
Am J Gastroenterol. 2009 Oct;104(10):2458-66
pubmed: 19532126
Gastroenterology. 2002 Dec;123(6):1839-47
pubmed: 12454841
Semin Liver Dis. 2018 Feb;38(1):87-96
pubmed: 29471569
Gastroenterology. 2018 May;154(6):1694-1705.e4
pubmed: 29360462
Liver Int. 2016 Mar;36(3):386-94
pubmed: 26212075
Hepatol Res. 2014 Aug;44(8):871-7
pubmed: 23819607
J Vasc Interv Radiol. 2006 Oct;17(10):1605-10
pubmed: 17057001
J Hepatol. 2010 Sep;53(3):397-417
pubmed: 20633946
Lancet. 2014 Nov 29;384(9958):1953-97
pubmed: 25433429
Gastroenterology. 2007 Sep;133(3):825-34
pubmed: 17678653
Hepatology. 2004 Sep;40(3):629-35
pubmed: 15349901
J Hepatol. 2006 Jan;44(1):217-31
pubmed: 16298014
J Hepatol. 2015 Apr;62(4):831-40
pubmed: 25463539
Z Gastroenterol. 2018 Jan;56(1):55-69
pubmed: 29316579
Am J Gastroenterol. 2003 Nov;98(11):2521-7
pubmed: 14638358
Clin Gastroenterol Hepatol. 2018 Jul;16(7):1153-1162.e7
pubmed: 29378312
Hepatol Commun. 2019 Mar 18;3(5):614-619
pubmed: 31061950
J Hepatol. 2015 Feb;62(2):332-9
pubmed: 25457205
Gut. 2010 Jul;59(7):988-1000
pubmed: 20581246
Am J Physiol Gastrointest Liver Physiol. 2016 Nov 1;311(5):G945-G953
pubmed: 27288426
J Vasc Interv Radiol. 2017 Jan;28(1):117-125
pubmed: 27553918
J Hepatol. 2018 Mar;68(3):563-576
pubmed: 29111320
Gastroenterology. 2003 Mar;124(3):634-41
pubmed: 12612902
World J Gastroenterol. 2014 Mar 14;20(10):2704-14
pubmed: 24627607
N Engl J Med. 1995 May 4;332(18):1192-7
pubmed: 7700312
Am J Gastroenterol. 1999 May;94(5):1361-5
pubmed: 10235219